Abstract
My personal memory with Prof. Kalevi Kairemo is related to our coworking
for biokinetics of radioactive iodine (RAI), and a couple of international conferences
organized by him. I presented my data on the dosimetric approach of RAI treatment for
differentiated thyroid cancer (DTC) at the conference in Helsinki. We analyzed the data
of our work and published a paper. Here I summarize my experience of working with
him. In summary, maximum permissible dose (MPD) therapy with dosimetry is
effective for a selected group ofhigh-risk DTC patients. Calculation of MPD is feasible
either by tracer and therapeutic doses and either by blood clearance method and
metaphase analysis of peripheral blood lymphocytes. The use of recombinant thyroidstimulating
hormone (rhTSH) changes the biokinetics of RAI. It needs further
investigation whether rhTSH can be used for MPD therapy of DTC.
Keywords: Differentiated Thyroid Cancer, Dosimetry, Radioactive Iodine Treatment.
Related Books
Advances in Cancer Nanotheranostics for Experimental and Personalized Medicine
Cancer Metastasis and Cancer Stem Cell/Niche
Cancer Preventive and Therapeutic Compounds: Gift From Mother Nature
Controversies in Neuro-Oncology
Current Advances in Breast Cancer Research: A Molecular Approach
Cutting Edge Therapies for Cancer in the 21st Century
Frontiers in Cancer Immunology
Frontiers in Cancer Immunology
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Frontiers in Clinical Drug Research - Anti-Cancer Agents